U. In this paper, the author analyzes the characteristics of. M amp； Aacute； s. to be exact, the current invention and amp； oacute； n refer to C amp； eacute； Lulas t.TRANSFECTED / TRANSDUCED WITH AN ANTI-GENE UNION RECEIVER THAT IS ATTRACTED BY THE UNION / SPECIFIC INTERACTION WITH THE DOMAIN FC MUTATED FROM THERAPEUTIC ANTIBODIES. IN ADDITION, THE INVENTION IS REFERRED TO A KIT THAT INCLUDES THE T-CELLS OF THE INVENTION AND / OR MOLEACULES OF NUCLEIC ACIDS,VECTORS EXPRESSING AN ANTI-GENE RECEIVERS OF THE PRESENT INVENTION AND ONE OR MORE ANTIBODIES WITH TUMORAL TARGET THAT INCLUDE A MUTATED FC DOMAIN. THE INVENTION FURTHER PROVIDES THE PRODUCTION AND USE OF CEULAS T IN A METHOD FOR THE TREATMENT OF PARTICULAR DISEASES, AS WELL AS TUMORAL ANTIBODIES. AS PHARMACEUTICAL COMPOSITIONS / MEDICINES INCLUDING CE TITLES AND / OR THERAPEUTIC ANTIBODIES,C amp； eacute； Lulas t must combine CI amp； oacute； n M amp； Aacute； s antibody with Diana tumor therapy and amp； eacute； uticos, including Fc domain with uni amp mutation； oacute； n reduction to FC. lt； / P gt receiver；<；p>；LA PRESENTE INVENCIÓ；N SE REFIERE DE MANERA GENERAL A RECEPTORES DE UNIÓ；N A ANTÍ；GENO CAPACES DE UNIÓ；N ESPECÍ；FICA A DOMINIOS FC MUTADOS CON UNIÓ；N A RECEPTOR FC REDUCIDA Y CÉ；LULAS T QUE EXPRESAN DICHOS RECEPTORES DE UNIÓ；N A ANTÍ；GENO. MÁ；S EXACTAMENTE, LA PRESENTE INVENCIÓ；N SE REFIERE A CÉ；LULAS T, TRANSFECTADAS/TRANSDUCIDAS CON UN RECEPTOR DE UNIÓ；N A ANTÍ；GENO QUE RESULTA ATRAÍ；DO POR LA UNIÓ；N/INTERACCIÓ；N ESPECÍ；FICA CON EL DOMINIO FC MUTADO DE ANTICUERPOS TERAPÉ；UTICOS. ADEMÁ；S, LA INVENCIÓ；N SE REFIERE A UN KIT QUE COMPRENDE LAS CÉ；LULAS T DE LA INVENCIÓ；N Y/O MOLÉ；CULAS DE Á；CIDOS NUCLEICOS, VECTORES QUE EXPRESAN RECEPTORES DE UNIÓ；N A ANTÍ；GENO DE LA PRESENTE INVENCIÓ；N Y UNO O MÁ；S ANTICUERPOS CON DIANA T
